Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dr Oregonin Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner in a distinct art unit. This indicates a focus for the company's current biotechnology patenting efforts, where an application represents the entirety of its active prosecution before the USPTO. Such a focused portfolio allows for a deep dive into the specific technical and legal issues raised by the examiner in the biotechnology field.
The busiest examiner for the company is LI, WENHAN, who oversees 1 busiest examiner pending office action. Since there is a pending action in the portfolio, LI, WENHAN is the examiner the company is currently working with. Practitioners should focus on the specific guidelines of the art unit involved to navigate this pending matter effectively. Success in this instance will require a thorough understanding of LI's examination style and the specific requirements for pharmaceutical and biotechnological disclosures within the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, WENHAN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18826763 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING PERIODONTAL DISEASES CONTAINING EXTRACT OF ALNUS JAPONICA PLANT EXTRACTS AS ACTIVE INGREDIENT, FOOD COMPOSITION FOR ALLEVIATING PERIODONTAL DISEASES CONTAINING SAME AND TOOTHPASTE AND FEED CONTAINING SAME | LI, WENHAN | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18826763 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING PERIODONTAL DISEASES CONTAINING EXTRACT OF ALNUS JAPONICA PLANT EXTRACTS AS ACTIVE INGREDIENT, FOOD COMPOSITION FOR ALLEVIATING PERIODONTAL DISEASES CONTAINING SAME AND TOOTHPASTE AND FEED CONTAINING SAME | LI, WENHAN | 1614 | §102§103 | Non-Final OA | — | Pending | Sep 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDr Oregonin Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Wenhan Li has the most, with 1 of Dr Oregonin Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
